Found: 341
Select item for more details and to access through your institution.
Subclinical immune responses to nickel in sensitized individuals—a dose–response study.
- Published in:
- Contact Dermatitis (01051873), 2024, v. 91, n. 1, p. 1, doi. 10.1111/cod.14549
- By:
- Publication type:
- Article
Topical corticosteroids in the era of new topical therapies: Balancing efficacy and safety for long‐term use.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 7, p. 1236, doi. 10.1111/jdv.20041
- By:
- Publication type:
- Article
Impact of climate change on atopic dermatitis: A review by the International Eczema Council.
- Published in:
- Allergy, 2024, v. 79, n. 6, p. 1455, doi. 10.1111/all.16007
- By:
- Publication type:
- Article
RNA‐sequencing of paired tape‐strips and skin biopsies in atopic dermatitis reveals key differences.
- Published in:
- Allergy, 2024, v. 79, n. 6, p. 1548, doi. 10.1111/all.16086
- By:
- Publication type:
- Article
Erenumab for Treatment of Persistent Erythema and Flushing in Rosacea: A Nonrandomized Controlled Trial.
- Published in:
- JAMA Dermatology, 2024, v. 160, n. 6, p. 612, doi. 10.1001/jamadermatol.2024.0408
- By:
- Publication type:
- Article
Fatigue is associated with disease severity in adult patients with hidradenitis suppurativa.
- Published in:
- JEADV Clinical Practice, 2024, v. 3, n. 2, p. 769, doi. 10.1002/jvc2.345
- By:
- Publication type:
- Article
Inflammatory plasma signature of chronic hand eczema: Associations with aetiological and clinical subtypes.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 6, p. 1101, doi. 10.1111/jdv.19742
- By:
- Publication type:
- Article
Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study.
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 5, p. 769, doi. 10.1093/bjd/ljae042
- By:
- Publication type:
- Article
Attitudes towards clinical research in adult patients with hidradenitis suppurativa during the COVID-19 pandemic: Insights from a survey.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 5, p. e371, doi. 10.1111/jdv.19758
- By:
- Publication type:
- Article
Prevalence and incidence of hand eczema in healthcare workers: A systematic review and meta‐analysis.
- Published in:
- Contact Dermatitis (01051873), 2024, v. 90, n. 4, p. 331, doi. 10.1111/cod.14489
- By:
- Publication type:
- Article
Predicting Psoriatic Arthritis in Psoriasis Patients – A Swiss Registry Study.
- Published in:
- Journal of Psoriasis & Psoriatic Arthritis, 2024, v. 9, n. 2, p. 41, doi. 10.1177/24755303231217492
- By:
- Publication type:
- Article
Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT).
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 4, p. 719, doi. 10.1111/jdv.19730
- By:
- Publication type:
- Article
Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis.
- Published in:
- Dermatology (10188665), 2024, v. 240, n. 2, p. 243, doi. 10.1159/000535285
- By:
- Publication type:
- Article
Comorbidity burden in adult atopic dermatitis: A population-based study.
- Published in:
- JEADV Clinical Practice, 2024, v. 3, n. 1, p. 128, doi. 10.1002/jvc2.303
- By:
- Publication type:
- Article
The vIGA‐AD scale for atopic dermatitis: Uptake in the past 5 years and position of the International Eczema Council.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 3, p. e291, doi. 10.1111/jdv.19627
- By:
- Publication type:
- Article
Tralokinumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients aged 12 years and older with and without atopic comorbidities.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii46, doi. 10.1093/bjd/ljad498.048
- By:
- Publication type:
- Article
Improvement of the head and neck regions with continuous tralokinumab treatment for up to 4 years in adults with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii49, doi. 10.1093/bjd/ljad498.051
- By:
- Publication type:
- Article
Atopic dermatitis phenotypes based on cluster analysis of the Danish Skin Cohort.
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 2, p. 207, doi. 10.1093/bjd/ljad401
- By:
- Publication type:
- Article
Comorbidities in childhood atopic dermatitis: A population‐based study.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 2, p. 354, doi. 10.1111/jdv.19569
- By:
- Publication type:
- Article
Higher occurrence of ocular surface disease symptoms in patients with atopic dermatitis—Data in the FOREVER study.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
Treat-to-Target in Atopic Dermatitis.
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 1, p. 91, doi. 10.1007/s40257-023-00827-y
- By:
- Publication type:
- Article
Treat‐to‐target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitis.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 1, p. 42, doi. 10.1111/jdv.19506
- By:
- Publication type:
- Article
Predicting discontinuation of biologic therapy caused by adverse events in psoriasis patients—A Danish nationwide cohort study.
- Published in:
- JEADV Clinical Practice, 2023, v. 2, n. 4, p. 792, doi. 10.1002/jvc2.219
- By:
- Publication type:
- Article
Mapping the road to biologics in psoriasis and psoriatic arthritis: A nationwide drug utilization study.
- Published in:
- JEADV Clinical Practice, 2023, v. 2, n. 4, p. 857, doi. 10.1002/jvc2.194
- By:
- Publication type:
- Article
Upadacitinib treatment withdrawal and retreatment in patients with moderate‐to‐severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 12, p. 2558, doi. 10.1111/jdv.19391
- By:
- Publication type:
- Article
No associations between type 1 diabetes and atopic dermatitis, allergic rhinitis, or asthma in childhood: a nationwide Danish case-cohort study.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-47292-5
- By:
- Publication type:
- Article
Impact of the COVID-19 Pandemic on Care for Patients With Atopic Dermatitis.
- Published in:
- 2023
- By:
- Publication type:
- Letter to the Editor
Limited clinical role of blood eosinophil levels in early life atopic disease: A mother–child cohort study.
- Published in:
- Pediatric Allergy & Immunology, 2023, v. 34, n. 11, p. 1, doi. 10.1111/pai.14050
- By:
- Publication type:
- Article
A Skin Care Program to Prevent Skin Problems due to Diabetes Devices in Children and Adolescents: A Cluster-Controlled Intervention Study.
- Published in:
- Diabetes Care, 2023, v. 46, n. 10, p. 1770, doi. 10.2337/dc23-0462
- By:
- Publication type:
- Article
A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 10, p. 2041, doi. 10.1111/jdv.19255
- By:
- Publication type:
- Article
Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16.
- Published in:
- Advances in Therapy, 2023, v. 40, n. 8, p. 3574, doi. 10.1007/s12325-023-02528-8
- By:
- Publication type:
- Article
Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis.
- Published in:
- Clinical & Experimental Dermatology, 2023, v. 48, n. 8, p. 881, doi. 10.1093/ced/llad129
- By:
- Publication type:
- Article
Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 4, p. 595, doi. 10.1007/s40257-023-00792-6
- By:
- Publication type:
- Article
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 4, p. 609, doi. 10.1007/s40257-023-00785-5
- By:
- Publication type:
- Article
Circulating biomarkers are associated with disease severity of chronic hand eczema and atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 1, p. 114, doi. 10.1093/bjd/ljad110
- By:
- Publication type:
- Article
Treatment with delgocitinib cream improves itch, pain and other signs and symptoms of chronic hand eczema: Results from the Hand Eczema Symptom Diary in a phase IIb randomized clinical trial.
- Published in:
- Contact Dermatitis (01051873), 2023, v. 89, n. 1, p. 46, doi. 10.1111/cod.14303
- By:
- Publication type:
- Article
Association between atopic dermatitis/eczema and arthritis among US adults.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 7, p. e855, doi. 10.1111/jdv.18958
- By:
- Publication type:
- Article
Diagnosis and Management of Pediatric Chronic Hand Eczema: The PeDRA CACHES Survey.
- Published in:
- Pediatric Drugs, 2023, v. 25, n. 4, p. 459, doi. 10.1007/s40272-023-00574-x
- By:
- Publication type:
- Article
395 Assessing imputation methods with the lebrikizumab clinical trial program.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.020
- By:
- Publication type:
- Article
373 Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: data from eight trials.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.004
- By:
- Publication type:
- Article
400 Efficacy of lebrikizumab in patients who did not achieve protocol-defined criteria for response after initial 16 weeks of therapy.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.023
- By:
- Publication type:
- Article
381 Improved and cleared facial and hand dermatitis with lebrikizumab in patients with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.009
- By:
- Publication type:
- Article
409 Efficacy and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: subgroup analysis of the Measure Up 1, Measure Up 2 and AD Up phase 3 clinical trials at 52 weeks.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.030
- By:
- Publication type:
- Article
380 Patients maintain stable response with no or minimal fluctuations during treatment with lebrikizumab up to Week 52.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.008
- By:
- Publication type:
- Article
393 Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis without topical corticosteroids: an updated network meta-analysis.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.018
- By:
- Publication type:
- Article
419 Patient satisfaction with treatments for moderate-to-severe atopic dermatitis according to degree and speed of skin and itch improvements: results from a patient survey in the United States.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.039
- By:
- Publication type:
- Article
427 Long-term 4-year safety of upadacitinib in moderate-to-severe atopic dermatitis: results of an integrated analysis of phase 3 studies.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.047
- By:
- Publication type:
- Article
424 Effect of abrocitinib vs. dupilumab on skin pain: an analysis of the phase 3 JADE COMPARE and JADE DARE trials.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.044
- By:
- Publication type:
- Article
414 Baseline serum biomarkers do not predict dupilumab treatment response in adults with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.034
- By:
- Publication type:
- Article
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
- Published in:
- British Journal of Dermatology, 2023, v. 188, n. 6, p. 740, doi. 10.1093/bjd/ljad022
- By:
- Publication type:
- Article